Akero Therapeutics
AKRO
AKRO was delisted on the 8th of December, 2025.
102 hedge funds and large institutions have $888M invested in Akero Therapeutics in 2020 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 40 increasing their positions, 23 reducing their positions, and 6 closing their positions.
383% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 6
74% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 23
63% more capital invested
Capital invested by funds: $545M → $888M (+$343M)
29% more funds holding
Funds holding: 79 → 102 (+23)
7.3% more ownership
Funds ownership: 76.24% → 83.54% (+7.3%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
79% less call options, than puts
Call options by funds: $289K | Put options by funds: $1.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
+$67.9M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$62.4M |
| 3 |
Alkeon Capital Management
New York
|
+$44.8M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$27.9M |
| 5 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
+$21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VVM
Versant Venture Management
San Francisco,
California
|
-$46.8M |
| 2 |
VP
venBio Partners
San Francisco,
California
|
-$24.7M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$10.6M |
| 4 |
Morgan Stanley
New York
|
-$4.49M |
| 5 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$2.37M |
AKRO Hedge Fund Activity: Q3 2020 in Review
102 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Akero Therapeutics (AKRO) for Q3 2020, worth a combined $888M — up 63% from $545M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new AKRO positions and 6 closed out — a net gain of 23 holders — while 40 added to existing stakes and 23 trimmed.
The largest buyer was Redmile Group, adding an estimated $67.9M. The largest seller was Versant Venture Management, cutting an estimated $46.8M.
- 102 institutional investors held Akero Therapeutics (AKRO) as of Q3 2020, up from 79 in Q2 2020.
- Funds reported $888M of Akero Therapeutics stock for Q3 2020, up 63% quarter-over-quarter.
- 29 funds opened new Akero Therapeutics positions in Q3 2020 and 6 closed out, a net change of +23 holders.
- The largest Akero Therapeutics buyer in Q3 2020 was Redmile Group, an estimated $67.9M added.
- The largest Akero Therapeutics seller in Q3 2020 was Versant Venture Management, an estimated $46.8M sold.
Based on aggregated 13F filings for Q3 2020.